Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

OBJECTIVE: To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:RMD Open
Main Authors: Walker, Ulrich A, Tilson, Hugh H, Hawkins, Philip N, van der Poll, Tom, Noviello, Stephanie, Levy, Jeremy, Vritzali, Eleni, Hoffman, Hal M, Kuemmerle-Deschner, Jasmin B
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2021
Assuntos:
Autoinflammatory Disorders
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130749/
https://ncbi.nlm.nih.gov/pubmed/34001647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2021-001663
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares